Trials / Completed
CompletedNCT01069419
Observation of Treatment With Certolizumab Pegol in Daily Practice
A Multicenter, Observational, Non-interventional Study to Evaluate the Safety and Efficacy of Anti-TNF (Anti-Tumor Necrosis Factor) Alpha Therapy With Certolizumab Pegol Observed in Daily Practice in Adult Rheumatoid Arthritis (RA) Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,117 (actual)
- Sponsor
- UCB Pharma GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an observational, non-interventional, non-comparative, post-authorization safety study to evaluate efficacy and long-term safety of Cimzia in adult patients with RA in need of treatment with a biological product.
Detailed description
The purpose of this study is to assess the clinical efficacy of Cimzia in achieving clinical remission after two years of therapy. The observational nature of the study leaves the therapeutic decision exclusively within the discretion of the treating physician.
Conditions
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2014-09-01
- Completion
- 2014-12-01
- First posted
- 2010-02-17
- Last updated
- 2015-10-29
- Results posted
- 2015-09-29
Locations
163 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01069419. Inclusion in this directory is not an endorsement.